547 filings
Page 2 of 28
8-K
2rg5k2m8pk5
11 May 23
ProPhase Labs Announces Financial Results
8:10am
ARS
89y81ztc2 srm
27 Apr 23
Annual report to shareholders
8:05am
8-K
qngptuibpobewb9t
25 Apr 23
Regulation FD Disclosure
8:20am
8-K
ascmx9a0j yyae1f0
6 Apr 23
Departure of Directors or Certain Officers
4:15pm
8-K
iv0sa htr89lm5z98hu
28 Mar 23
ProPhase Labs Announces Record Financial Results
8:05am
8-K
0ttgvmwqdvh
15 Mar 23
ProPhase Labs Announces New $6 Million Stock Repurchase Program
8:05am
8-K
9j6w9jmc0iqodmap
1 Mar 23
Company in Early Stages of Exploring Development for Commercialization in Other Countries
8:05am
8-K
ffc99t
22 Feb 23
Goal to launch commercially in Q4 2023
8:05am
8-K
pbsy jrzqo
15 Feb 23
ProPhase Labs Announces Plans for Major Expansion of its Pharmaloz Manufacturing, Inc. Subsidiary to Meet Growing Demand
8:05am
8-K
uiyje tx1qfbd
6 Feb 23
ProPhase Labs Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy
9:29am
8-K
hi2utp
30 Jan 23
Entry into a Material Definitive Agreement
4:30pm
8-K
8kzz3gar fcqv
5 Jan 23
ProPhase Labs Closes Acquisition of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test
8:10am
8-K
0k1m9
28 Dec 22
Departure of Directors or Certain Officers
4:15pm
8-K
uho2man2 h08c6ro5
20 Dec 22
ProPhase Labs Acquires Rights to Novel Esophageal Cancer Test
8:30am
S-8
2vp3hjd4908tpg4
14 Nov 22
Registration of securities for employees
5:03pm
8-K
b48dj8qbdcnknnp5in
10 Nov 22
ProPhase Labs Announces Record Third Quarter 2022 Financial Results
8:55am
8-K
0e052xtt6zvxs3p zd
8 Nov 22
ProPhase Labs Announces Collaboration with Dana-Farber Cancer Institute
8:05am